Advertisement
News
Advertisement

Foundation Venture Capital Group Invests In Company Developing Implantable Meniscus for Knee Repair

Thu, 04/18/2013 - 2:13pm
Bio-Medicine.Org

NEW BRUNSWICK, N.J., April 18, 2013 /PRNewswire-USNewswire/ -- Newly formed NovoPedics, Inc., has received a commitment of up to $500,000 from Foundation Venture Capital Group (FVCG) to advance its development of an implantable meniscus replacement/regeneration medical device.

Currently in the United States, the treatment options for pain after meniscectomy are limited to replacement with allograft (cadaver) tissue, bone realignment surgeries and knee replacement surgery; there is no FDA-approved product for replacement of the meniscus.

Meniscofix™, the company's first product, uses a biodegradable polymer fiber-reinforced scaffold that restores mobility to patients suffering from severe meniscus knee injuries and can prevent the long-term development of arthritis.  

"There are more than 1.5 million meniscus tears each year, resulting in 800,000 meniscectomy surgeries," explained Dr. Charles Gatt and Dr. Michael Dunn , company founders.  "Meniscofix is an innovative way to repair these tears and may also eliminate the development of arthritis that is often a complication of current meniscus repair surgery.  Meniscofix has a unique fiber-reinforced design similar to the native meniscus and can be attached to either soft tissue or bone, allowing it to be used in either partial or total meniscus replacement surgery."

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading